Towards a cure for food allergy

Current Opinion in Immunology

Volumn 20, Issue 6, 2008, Pages 690-696

  Skripak, Justin M ^a   Sampson, Hugh A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAHF 2; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; OMALIZUMAB; PLACEBO; TBX 901; UNCLASSIFIED DRUG;

CHINESE MEDICINE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG FORMULATION; FOOD ALLERGY; HERBAL MEDICINE; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DENATURATION; PROTEIN INTAKE; REVIEW; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DRUGS, CHINESE HERBAL; FOOD HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; RECOMBINANT PROTEINS;

EID: 56449119790     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.09.002     Document Type: Review

References (51)

1. Ross M.P., Ferguson M., Street D., Klontz K., Schroeder T., and Luccioli S. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol 121 (2008) 166-171
2. Colver A.F., Nevantaus H., Macdougall C.F., and Cant A.J. Severe food-allergic reactions in children across the UK and Ireland, 1998-2000. Acta Paediatr 94 (2005) 689-695
3. de Silva I.L., Mehr S.S., Tey D., and Tang M.L. Paediatric anaphylaxis: a 5 year retrospective review. Allergy 63 (2008) 1071-1076
4. Le Borgne M., Etchart N., Goubier A., Lira S.A., Sirard J.C., van Rooijen N., Caux C., Ait-Yahia S., Vicari A., Kaiserlian D., and Dubois B. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 24 (2006) 191-201
5. Allam J.P., Niederhagen B., Bucheler M., Appel T., Betten H., Bieber T., Berge S., and Novak N. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 61 (2006) 166-172
6. Allam J.P., Stojanovski G., Friedrichs N., Peng W., Bieber T., Wenzel J., and Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy 63 (2008) 720-727. This paper describes the variation in the phenotype of mast cells and Langerhans cells at various sites within the oral mucosa. This has the clinical implication of potentially pinpointing targeted delivery of immunotherapeutic agents to immunologically favoured sites.
7. Greer F.R., Sicherer S.H., and Burks A.W. American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Allergy and Immunology: effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 121 (2008) 183-191. This article provides a summary of the current evidence for the role early diet may play in the development of sensitization and subsequent allergic disease.
8. von Berg A., Filipiak-Pittroff B., Kramer U., Link E., Bollrath C., Brockow I., Koletzko S., Grubl A., Heinrich J., Wichmann H.E., et al. Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 121 6 (2008) 1442-1447. This is the largest prospective comparative study on the risk of developing allergic disease in infants fed standard cow's milk formula (CMF) compared with hydrolyzed CMFs. Those who received partially or extensively hydrolyzed casein-based formulas [but not a whey-based hydrolysate] had a reduced risk of allergic disease up to six years of age.
9. Dalal I., Binson I., Reifen R., Amitai Z., Shohat T., Rahmani S., Levine A., Ballin A., and Somekh E. Food allergy is a matter of geography after all: sesame as a major cause of severe IgE-mediated food allergic reactions among infants and young children in Israel. Allergy 57 (2002) 362-365
10. Du Toit G., Katz Y., Sasiani P., Nitzan Kaluski D., Irit Livne I., and Lack G. Different prevalence of peanut allergy in children in Israel and UK is not due to differences in atopy. J Allergy Clin Immunol 117 (2005) S33
11. Sicherer S.H., and Sampson H.A. Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 120 (2007) 491-503
12. Eigenmann P.A., Asigbetse K.E., and Frossard C.P. Avirulant Salmonella typhimurium strains prevent food allergy in mice. Clin Exp Immunol 151 (2008) 546-553
13. Frossard C.P., Steidler L., and Eigenmann P.A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119 (2007) 952-959. In a mouse model of food allergy, delivery of IL-10 to the gut mucosa prevented sensitization to β-Lactoglobulin (BLG), as demonstrated by a significant suppression in anaphylaxis to BLG gastric challenge and by decreased BLG-specific IgE and IgG1 antibodies.
14. Zhu F.G., Kandimalla E.R., Yu D., and Agrawal S. Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol 120 3 (2007) 631-637
15. Nelson H.S., Lahr J., Rule R., Bock A., and Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99 (1997) 744-751
16. Oppenheimer J.J., Nelson H.S., Bock S.A., Christensen F., and Leung D.Y. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90 (1992) 256-262
17. Patriarca G., Schiavino D., Nucera E., Schinco G., Milani A., and Gasbarrini G.B. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology 45 (1998) 52-58
18. Patriarca G., Nucera E., Roncallo C., Pollastrini E., Bartolozzi F., De Pasquale T., Buonomo A., Gasbarrini G., Di Campli C., and Schiavino D. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 17 (2003) 459-465
19. Patriarca G., Nucera E., Pollastrini E., De Pasquale T., Lombardo C., Buonomo A., Roncallo C., Pecora V., Musumeci S., Altomonte G., et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci 51 (2006) 471-473
20. Patriarca G., Nucera E., Pollastrini E., Roncallo C., De Pasquale T., Lombardo C., Pedone C., Gasbarrini G., Buonomo A., and Schiavino D. Oral specific desensitization in food-allergic children. Dig Dis Sci 52 (2007) 1662-1672
21. Buchanan A.D., Green T.D., Jones S.M., Scurlock A.M., Christie L., Althage K.A., Steele P.H., Pons L., Helm R.M., Lee L.A., and Burks A.W. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119 (2007) 199-205
22. A/L. The treatment was generally well tolerated, and effectively desensitized a subset of subjects.
23. Morisset M., Moneret-Vautrin D.A., Guenard L., Cuny J.M., Frentz P., Hatahet R., Hanss C., Beaudouin E., Petit N., and Kanny G. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol 39 (2007) 12-19
24. Staden U., Blumchen K., Blankenstein N., Dannenberg N., Ulbricht H., Dobberstein K., Ziegert M., Niggemann B., Wahn U., and Beyer K. Rush oral immunotherapy in children with persistent cow's milk allergy. J Allergy Clin Immunol 62 (2008) 1261-1269
25. Staden U., Rolinck-Werninghaus C., Brewe F., Wahn U., Niggemann B., and Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 122 (2007) 418-419. This is an important paper that compared the ability of food-specific oral immunotherapy to induce long-term tolerance with an untreated control group. Although the treatment effectively raised the threshold dose for clinical reactivity in the majority of subjects, no difference in the acquisition of tolerance following treatment was seen compared with untreated controls.
26. Mansfield L. Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol 97 (2006) 266-267
27. Enrique E., Pineda F., Malek T., Bartra J., Basagana M., Tella R., Castello J.V., Alonso R., de Mateo J.A., Cerda-Trias T., et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116 (2005) 1073-1079. This is the only placebo-controlled trial of sublingual immunotherapy for food allergy. It is unclear whether a number of participants were truly allergic to hazelnut or whether they suffered from birch-related pollen-food allergy syndrome to hazelnut.
28. de Boissieu D., and Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy 61 (2006) 1238-1239
29. Panzner P., Petras M., Sykora T., and Lesna I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 102 (2008) 1296-1304
30. Vila L., Beyer K., Jarvinen K.M., Chatchatee P., Bardina L., and Sampson H.A. Role of conformational and linear epitopes in the achievement of tolerance in cow's milk allergy. Clin Exp Allergy 31 10 (2001) 1599-1606
31. Urisu A., Ando H., Morita Y., Wada E., Yasaki T., Yamada K., Komada K., Torii S., Goto M., and Wakamatsu T. Allergenic activity of heated and ovomucoid-depleted egg white. J Allergy Clin Immunol 100 2 (1997) 171-176
32. Nowak-Wegrzyn A., Bloom K.A., Sicherer S.H., Shreffler W.G., Noone S., Wanich N., and Sampson H.A. Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 122 (2008) 342-7, 347.e1-2. This study demonstrated that three fourths of cow's milk allergic children can tolerate extensively heated [baked or heat-denatured] milk. Immunologic changes associated with ingestion of baked-milk products suggest that it may have a similar effect as oral immunotherapy, but owing to the changes in conformational epitopes induced by high temperatures, it provides milk protein in a less allergenic form of the protein.
33. Glenting J., Poulsen L.K., Kato K., Madsen S.M., Frokiaer H., Wendt C., and Sorensen H.W. Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis. Microb Cell Fact 6 (2007) 28
34. King N., Helm R., Stanley J.S., Vieths S., Luttkopf D., Hatahet L., Sampson H., Pons L., Burks W., and Bannon G.A. Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res 49 (2005) 963-971
35. Li X.M., Srivastava K., Grishin A., Huang C.K., Schofield B., Burks W., and Sampson H.A. Persistent protective effect of heat-killed Escherichia coli producing 'engineered' recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112 (2003) 159-167
36. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., Davis F.M., Hyun J.D., and Shanahan Jr. W.R. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993. While the clinical threshold for reactivity to peanut was significantly increased in the majority of participants who received the high dose of anti-IgE, 25% received no benefit.
37. ® (omalizumab) in peanut allergy (TOPS). J Allergy Clin Immunol 119 (2007) S117
38. Srivastava K.D., Kattan J.D., Zou Z.M., Li J.H., Zhang L., Wallenstein S., Goldfarb J., Sampson H.A., and Li X.M. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115 (2005) 171-178
39. Qu C., Srivastava K., Ko J., Zhang T.F., Sampson H.A., and Li X.M. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 37 (2007) 846-855. A novel combination of Chinese herbs fed to a murine model of peanut allergy eliminated anaphylaxis following challenge with peanut allergen and induced a reduction of Th2 cytokines and elevation of Th1 cytokines produced by splenocytes in vitro stimulated with peanut extract compared with sham-treated mice.
40. Kattan J.D., Srivastava K.D., Zou Z.M., Goldfarb J., Sampson H.A., and Li X.M. Pharmacological and immunological effects of individual herbs in the Food Allergy Herbal Formula-2 (FAHF-2) on peanut allergy. Phytother Res 22 (2008) 651-659
41. Feng B.S., Chen X., He S.H., Zheng P.Y., Foster J., Xing Z., Bienenstock J., and Yang P.C. Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model. J Allergy Clin Immunol 122 (2008) 55-61, 61.e1-7
42. Kishida T., Hiromura Y., Shin-Ya M., Asada H., Kuriyama H., Sugai M., Shimizu A., Yokota Y., Hama T., Imanishi J., et al. IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J Immunol 179 (2007) 8554-8561. The administration of IL-21 prevented anaphylaxis to peanut and suppressed total and peanut-specific IgE in a murine model of peanut allergy. The authors proposed that IL-21 induced inhibitor of differentiation 2, which inhibited class switch recombination for IgE production.
43. Peng Z., Liu Q., Wang Q., Rector E., Ma Y., and Warrington R. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clin Exp Allergy 37 (2007) 1040-1048
44. Ando T., Hatsushika K., Wako M., Ohba T., Koyama K., Ohnuma Y., Katoh R., Ogawa H., Okumura K., Luo J., et al. Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance. J Allergy Clin Immunol 120 (2007) 916-923. TGF-β administered orally to mice exhibited an effect on the intestinal mucosa as demonstrated by increased Smad expression. It also enhanced the induction of oral tolerance to OVA when co-administered with OVA, resulting in decreased ability to induce the development of OVA-specific IgE.
45. Mertsching E., Bafetti L., Hess H., Perper S., Giza K., Allen L.C., Negrou E., Hathaway K., Hopp J., Chung J., et al. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J Allergy Clin Immunol 121 (2008) 441-447.e5. A mouse Fcε-Fcγ fusion protein suppressed the ability to sensitize mast cells in vitro. A human homologue of this protein prevented anaphylaxis to Ascaris in sensitized monkeys. The activity of this recombinant protein was dependent on the presence on FcγRIIB.
46. Mazuc E., Villoutreix B.O., Malbec O., Roumier T., Fleury S., Leonetti J.P., Dombrowicz D., Daeron M., Martineau P., and Dariavach P. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. J Allergy Clin Immunol 122 (2008) 188-94, 194.e1-3
47. Van Overtvelt L., Lombardi V., Razafindratsita A., Saint-Lu N., Horiot S., Moussu H., Mascarell L., and Moingeon P. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 145 (2008) 152-162
48. Sun J.B., Raghavan S., Sjoling A., Lundin S., and Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+ CD25+ and Foxp3- CD25- CD4+ regulatory T cells. J Immunol 177 (2006) 7634-7644
49. Huang C.F., Wang C.C., Wu T.C., Chu C.H., and Peng H.J. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice. Ann Allergy Asthma Immunol 99 (2007) 443-452
50. Mascarell L., Van Overtvelt L., Lombardi V., Razafindratsita A., Moussu H., Horiot S., Chabre H., Limal D., Moutel S., Bauer J., et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 26 (2007) 108-118
51. Razafindratsita A., Saint-Lu N., Mascarell L., Berjont N., Bardon T., Betbeder D., Van Overtvelt L., and Moingeon P. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 120 (2007) 278-285